Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196975 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,707
- Enrollment target
NCT01196975 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,707 participants.
The verdict
NCT01196975, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,707 participants
- Enrollment target
Study Summary
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines. This study will also evaluate the lot-to-lot consistency of three vaccine lots.
Interventions
- BIOLOGICAL Quadrivalent seasonal influenza vaccine GSK2282512A
- BIOLOGICAL FluLavalTM-VB
- BIOLOGICAL FluLavalTM-YB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,707 participants |
| Start Date | 2010-10-01 |
| Est. Completion | 2011-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01196975
The ClinicalTrials.gov registry entry for NCT01196975 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,707 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quadrivalent seasonal influenza vaccine GSK2282512A is the first listed.
NCT01196975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01196975 about?
NCT01196975 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults". This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines. This study will also evaluate the lot-to-lot consistency of three vaccine lots.
What is the current status of trial NCT01196975?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,707 participants. The study started on 2010-10-01. Estimated completion is 2011-06-24.
What interventions are being tested in trial NCT01196975?
The interventions under investigation include: Quadrivalent seasonal influenza vaccine GSK2282512A (BIOLOGICAL), FluLavalTM-VB (BIOLOGICAL), FluLavalTM-YB (BIOLOGICAL).
Who is sponsoring clinical trial NCT01196975?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.